Literature DB >> 11882493

High glucose abolishes the antiproliferative effect of 17beta-estradiol in human vascular smooth muscle cells.

Shanhong Ling1, Peter J Little, Maro R I Williams, Aozhi Dai, Kazuhiko Hashimura, Jun-Ping Liu, Paul A Komesaroff, Krishnankutty Sudhir.   

Abstract

We examined effects of 17beta-estradiol (E(2)) on human vascular smooth muscle cell (VSMC) proliferation under normal (5 mmol/l) and high (25 mmol/l) glucose concentrations. Platelet-derived growth factor (PDGF) BB (20 ng/ml)-induced increases in DNA synthesis and proliferation were greater in high than normal glucose concentrations; the difference in DNA synthesis was abolished by a protein kinase C (PKC)-beta inhibitor, LY-379196 (30 nmol/l). Western blotting showed that PKC-beta(1) protein increased in cells exposed to high glucose, whereas PKC-alpha protein and total PKC activity remained unchanged, compared with normal glucose cultures. In normal glucose, E(2) (1-100 nmol/l) inhibited PDGF-induced DNA synthesis by 18-37% and cell proliferation by 16-22% in a concentration-dependent manner. The effects of E(2) were blocked by the estrogen receptor (ER) antagonist ICI-182780, indicating ER dependence. In high glucose, the inhibitory effect of E(2) on VSMC proliferation was abolished but was restored in the presence of the PKC-beta inhibitor LY-379196. Thus high glucose enhances human VSMC proliferation and attenuates the antiproliferative effect of E(2) in VSMC via activation of PKC-beta.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11882493     DOI: 10.1152/ajpendo.00111.2001

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  6 in total

Review 1.  Therapeutic potential for protein kinase C inhibitor in vascular restenosis.

Authors:  Richard Qinxue Ding; Jerry Tsao; Hong Chai; Daria Mochly-Rosen; Wei Zhou
Journal:  J Cardiovasc Pharmacol Ther       Date:  2010-12-23       Impact factor: 2.457

Review 2.  Protein Kinase C as Regulator of Vascular Smooth Muscle Function and Potential Target in Vascular Disorders.

Authors:  H C Ringvold; R A Khalil
Journal:  Adv Pharmacol       Date:  2016-07-18

3.  Estrogen receptor-α but not -β or GPER inhibits high glucose-induced human VSMC proliferation: potential role of ROS and ERK.

Authors:  Jana Ortmann; Martha Veit; Sandra Zingg; Stefano Di Santo; Tobias Traupe; Zijiang Yang; Jan Völzmann; Raghvendra K Dubey; Stephan Christen; Iris Baumgartner
Journal:  J Clin Endocrinol Metab       Date:  2010-10-20       Impact factor: 5.958

Review 4.  Estrogen and the cardiovascular system.

Authors:  A A Knowlton; A R Lee
Journal:  Pharmacol Ther       Date:  2012-03-28       Impact factor: 12.310

Review 5.  Evolving mechanisms of vascular smooth muscle contraction highlight key targets in vascular disease.

Authors:  Zhongwei Liu; Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2018-02-13       Impact factor: 5.858

6.  Anti-proliferative activity of oral anti-hyperglycemic agents on human vascular smooth muscle cells: thiazolidinediones (glitazones) have enhanced activity under high glucose conditions.

Authors:  Peter J Little; Narin Osman; Stephanie T de Dios; Nelly Cemerlang; Mandy Ballinger; Julie Nigro
Journal:  Cardiovasc Diabetol       Date:  2007-10-28       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.